TARO: Taro Pharmaceutical Industries Ltd. - Summary | Jitta

Taro Pharmaceutical Industries Ltd.

NYSE:TARO

Price
$69.08
Loss Chance
48.4%
3.93JITTA SCORE
0.50%Under Jitta Line
Jitta Ranking
145 / 852
2,123 / 4,192
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (11)
Financial Strength (78)
Return to Shareholders (49)
Competitive Advantage (32)
Jitta Signs
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
CapExVery Low
Revenue and EarningRevenue decline from 2017-2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 12.42% in the last year
SG&A to SalesIncreasing Every Year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.93
0.50%
2.21
113.62%
2.42
505.97%
Pharmaceuticals
7.91
66.44%
3.29
53.06%
5.59
17.35%
COMPANY DESCRIPTION
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. It also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. The company offers its products primarily in the areas of topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, anti-inflammatory, and other therapeutic categories. The company distributes and sells its products directly to wholesalers, retail drug store chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.